What’s Really Going On & Why PCOS.com Exists

I’m Sean Sullivan  Co-Founder of PCOS.com, CEO and Founder of Vertical Health Network and (some might say) a jaded former insurance professional that for more than a decade worked at very near the highest levels of the health insurance industry. Back when I got started in the industry there were problems, but they were different than the ones facing everyday Americans today. In 2010 even minor pre-existing conditions could prevent Americans from obtaining health insurance coverage. In 2025, you can’t be denied access for pre-x, but you can basically be denied the real ability to use your insurance coverage because of just how broken the entire system is. Blocking most people from actually using their benefits, are massive out of pocket costs that have to be paid first before the insurance carrier pays for anything. That number can be as high as $20,000 for a family.

I got started in the business back in 2010 because I had hoped that coming changes were actually going to improve access for everyone. My prior company Health Network Group filled a massive void in the market, as consumers needed a safe and truly consumer focused path to research and enroll in a plan. Our company looked at what existed in the space, and found the holes that needed to be filled in and identified the areas that caused the most frustration for consumers. By 2013 our self-funded start-up had reached in excess of 10 million households annually. From 2013 on, that business continued to reach tens of millions of American households and – what I’m most proud of, is that we never dropped the ball so badly that anyone complained to the BBB or any other complaints site.

To this day, still zero complaints. 

Here’s a big part of the secret sauce, just be real with yourself. If you remove the obvious consumer traps (like robocalls) and you create a moat of good around your customers – your business can become popular with consumers, quickly. Creating that moat of good isn’t easy, but the truth is – it’s not that difficult to figure out how to create a good consumer experience. It’s just harder to execute on, but duh nothing that’s easy is actually good.

I ended up leaving the health insurance industry in 2021, despite a really excellent company Allstate, as in the Allstate – being the home for my prior business. Most of my team members have stayed on at Allstate and they continue to be a bright light in a very turbulent industry.

My reason to leave really had nothing to do with Allstate. I left because I’m an entrepreneur and person that doesn’t have the ability to unsee or forget things.  Once I know something, especially if it’s information that reveals a hard truth about something that could really help people – I can’t let it go. I chalk this up to my difficult childhood. I’ll spare you the details but the TLDR is those less than ideal life experiences seem to drive me to want to help other people. I’m always polite and professional, but I’ll be the first to admit I have a difficult time filtering myself in professional settings in healthcare.

From Being A Skeptic – To Discovering The Data That Convinced Me About GLP-1’s

So back in 2020 it was highly unlikely that I’d get involved with the pharmaceutical industry. I’m a data guy, but remember I’m jaded about healthcare. So in 2020 some individuals in healthcare that I respect and trust approached me about GLP-1’s. Reflexively I rejected their suggestion that I take a look at what’s going on with GLP-1 medications. I distrusted big pharma and being in my 40’s I still remembered “Phen Phen” the weight loss drug. They quickly countered with, these don’t work remotely like anything from the past, especially “phen phen”.

So I did a real 90 day deep dive. I’m not trying to toot my horn, but I’m sort of known as being the kind of nerd that’s going to learn too much. I’m known for digging too deep at times.

I came out of that deep dive convinced of many things, but these two I think were the most motivating.

#1 these GLP-1’s are in fact a safe breakthrough drug for treating T2D, obesity and other conditions.

#2 had these GLP-1’s been released 15 years earlier, a parent of mine might still be alive.

Then I learned the hard truth facing Americans. These breakthrough drugs are going to be in limited supply for years. Even worse when there are actually enough of them available for everyone in need – financially more than half of the country has zero ability to afford them. I didn’t need more convincing, but after also finding out that generic versions of these expensive drugs are going to be available in China and India six years before the United States – that’s an obvious national security issue in the making and that really pushed me over the top.

Healthcare is really difficult. Pharma is even worse. It didn’t matter. I already knew the truth about GLP-1’s.

So I started examining all of these applications for GLP-1’s and one area that there’s incredible evidence for is the treatment of PCOS. Learning that also struck a nerve for me because a couple close family friends had been unsuccessfully trying to have a child for more than a decade. More than 15 rounds of IVF and in excess of $300,000 spent over a decade. Massive lifestyle changes, huge effort made by both individuals. It didn’t matter.

It’s not easy to watch people you love that would be incredible parents, never actually conceive. It’s even harder to see one of them lose a child far into their pregnancy. They’re regular middle income Americans that basically wiped out their retirement fund by their mid forties just trying to have a child.

As I researched more and more about the reports of women that previously had been unable to conceive now being able to because of a GLP-1, I couldn’t help but think about my friends that spent over 10 years and their life savings trying to get pregnant just once. It reminded me of how I felt after realizing that had these GLP-1’s been released 15 years earlier one of my parents might still be alive.

Big Pharma & Big Insurance Have Failed Us

So you probably get the backstory of why I started PCOS.com for individuals seeking out a GLP-1 for PCOS treatment. There’s a mountain of data and evidence to support that GLP-1’s are truly a breakthrough drug that helps the body restore core functionality, and this can result in women previously unable to conceive to be able to.

I think it’s also important to disclose that the efforts aren’t just focused there. Our network also includes T2D.com for individuals that are diabetic or pre-diabetic, and Urgentcare.com for general health and wellness needs as well as for individuals seeking to treat obesity with a GLP-1 medication. All of these brands are designed to provide as much value as possible for the consumers that we serve.

Before I Get Into The Science On GLP-1’s & PCOS

One last thing I think is important to disclose. Big Pharma isn’t a fan of me or this business. In fact, because our goal is to make these life changing medications available to anyone that has real medical necessity – we’re often accused of being involved purely for financial reasons. They try to smear our name by saying our org is just trying to make money off of their hard work.

First, I think our organization is the only one that prices everything so that what our company makes on a per-patient basis is somewhere between $10 and $15 per month.

Really. That’s our business model.

Let’s see Eli Lilly and Novo Nordisk do the same thing… Unfortunately, they never will.

Okay so if you’ve made it this far, thanks – I really appreciate it. I’m all about transparency, so feel free to reach out. You can easily find me on LinkedIn.

So without further delay, here’s some more science focused information on why GLP-1’s are going to be a frontline treatment for PCOS moving forward. It doesn’t matter if big pharma likes it or not.

GLP-1 Medications: A New Era in Treating PCOS

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, impacting an estimated 1 in 10 globally. It is often misunderstood, underdiagnosed, and frustrating to manage due to its wide range of symptoms—irregular menstrual cycles, infertility, weight gain, insulin resistance, acne, and excessive hair growth.

For decades, treatment options have focused on symptom management rather than root causes: birth control pills to regulate cycles, metformin to address insulin resistance, and fertility medications to stimulate ovulation. But in recent years, GLP-1 receptor agonists – medications originally developed for diabetes and weight loss have entered the spotlight. Increasingly, these drugs are being recognized as a powerful, multifaceted therapy for PCOS, addressing both metabolic and reproductive health.

This article explores why GLP-1s are becoming a primary option for PCOS treatment, how they work, the evidence supporting their use, and what the future may hold for patients seeking better solutions.

Understanding the Link Between PCOS and Metabolism

To appreciate why GLP-1s are so promising, it’s important to understand PCOS’s metabolic foundation.

• Insulin Resistance: Up to 70% of women with PCOS have insulin resistance. This means their bodies produce more insulin than normal, which worsens hormone imbalances, increases testosterone levels, and contributes to weight gain.

• Obesity and Weight Gain: Extra weight amplifies PCOS symptoms, creating a cycle where insulin resistance leads to weight gain, which then worsens insulin resistance.

• Fertility Challenges: Insulin resistance and excess androgen production disrupt ovulation, making it harder for women with PCOS to conceive naturally.

Traditional treatments like metformin help improve insulin sensitivity, but many patients find the results modest. This is where GLP-1s – originally designed for type 2 diabetes – are rewriting the narrative.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It helps regulate blood sugar by stimulating insulin release, suppressing glucagon, and slowing gastric emptying.

GLP-1 receptor agonists (GLP-1 RAs) are medications that mimic this hormone. Popular examples include:

• Semaglutide (Ozempic®, Wegovy®)

• Liraglutide (Saxenda®, Victoza®)

• Dulaglutide (Trulicity®)

• Tirzepatide (Mounjaro®, Zepbound® – technically a dual GIP/GLP-1 agonist)

These drugs were first approved for diabetes and later for obesity management. But as researchers observed dramatic effects on weight, appetite control, and insulin sensitivity, interest grew in their potential for PCOS treatment.

Why GLP-1s Are a Game Changer for PCOS

1. Weight Loss and Appetite Control

GLP-1 medications consistently lead to significant weight reduction—often 10–20% of body weight. For women with PCOS, even modest weight loss (5–10%) can restore menstrual cycles and improve ovulation. GLP-1s make sustained weight loss achievable in a way that lifestyle changes and older medications rarely do.

2. Improved Insulin Sensitivity

By lowering insulin levels and improving glucose regulation, GLP-1s target one of the core drivers of PCOS. This improvement helps reduce excess androgen production, easing symptoms like acne, hair growth, and irregular cycles.

3. Restoring Fertility

A growing number of reports describe “Ozempic babies” – women who unexpectedly conceived after years of infertility. This isn’t magic – it’s biology. Weight loss and improved insulin control restore ovulation, dramatically improving chances of natural conception.

4. Reduced Cardiometabolic Risk

Women with PCOS face higher lifetime risks of type 2 diabetes, high blood pressure, and cardiovascular disease. GLP-1s lower blood sugar, blood pressure, and cholesterol while promoting weight loss, offering protection against these long-term risks.

5. Sustainable, Multi-System Benefits

Unlike birth control pills (which mask symptoms) or metformin (which offers limited metabolic help), GLP-1s address multiple aspects of PCOS simultaneously: weight, insulin, fertility, and long-term health risks.

What the Research Says

While large, PCOS-specific clinical trials are still limited, early evidence is promising:

• Weight and Insulin: Studies on liraglutide and semaglutide in women with PCOS show significant reductions in weight, insulin resistance, and androgen levels.

• Fertility Outcomes: Case reports and small trials suggest improved menstrual regularity and spontaneous ovulation after GLP-1 therapy.

• Combination Therapy: Some trials show enhanced effects when GLP-1s are combined with metformin, offering dual pathways for tackling insulin resistance.

For example, a 2023 review in the Journal of Clinical Medicine concluded that GLP-1s should be considered a frontline metabolic treatment in PCOS, especially for women struggling with obesity and insulin resistance. Here’s a link. 

Considerations and Limitations

1. Pregnancy and Safety

GLP-1s are not approved for use during pregnancy. Animal studies have raised concerns about fetal development, and all major guidelines recommend discontinuing the drug before conception. Women should stop GLP-1 use at least 1 – 2 months before trying to conceive.

2. Birth Control Interactions

Because GLP-1s slow digestion, they may reduce the effectiveness of oral contraceptives. Doctors often recommend non-oral or backup methods of contraception.

3. Cost and Access

Brand-name GLP-1 medications are expensive and often not covered by insurance for PCOS (since this is considered “off-label” use). However, compounded versions may improve affordability and access until patents expire in the USA.

The Patient Experience

Beyond the science, women with PCOS describe GLP-1s as life-changing.

Many report:

• Losing weight for the first time in years.

• Feeling in control of cravings and appetite.

• Getting their periods back after long absences.

• Conceiving naturally after infertility struggles.

These stories highlight what clinical trials are beginning to confirm: GLP-1s may offer not just symptom relief, but restoration of health and hope.

The Future of PCOS Care

The rise of GLP-1s represents a paradigm shift in PCOS management. Instead of treating isolated symptoms, these medications target the underlying metabolic dysfunction that drives the condition. In the coming years, we may see:

• Official guidelines endorsing GLP-1s for PCOS.

• Combination therapies pairing GLP-1s with metformin, inositol, or other medications.

• Personalized care models, where patients are screened for metabolic risk and matched to GLP-1 treatment early.

• Greater affordability as patents expire and generic or compounded options become widely available.

Conclusion

For too long, women with PCOS have faced limited treatment options and an uphill battle against weight, fertility challenges, and metabolic risks. GLP-1 medications are changing that narrative. By tackling the root metabolic dysfunctions of PCOS, they not only improve symptoms but also open the door to better reproductive outcomes and long-term health.

GLP-1s are not just another tool in the PCOS toolkit – they may be the foundation of a new standard of care.